{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T16:16:13Z","timestamp":1792167373218,"version":"4.4.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T00:00:00Z","timestamp":1720742400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T00:00:00Z","timestamp":1720742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>Diabetic nephropathy (DN) is the most common cause of end-stage kidney disease (ESKD). Remnant cholesterol has been investigated as a predictor for the progression of DN in type 1 diabetes mellitus patients, as well as the incidence of DN in type 2 diabetes mellitus (T2DM) patients. This study aimed to evaluate the longitudinal relationship between baseline remnant cholesterol and kidney outcomes using a Chinese T2DM with biopsy-confirmed DN cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We included 334 patients with T2DM and biopsy-confirmed DN during 2010\u20132019 West China Hospital T2DM-DN cohort. Remnant cholesterol was defined by Martin-Hopkins equation. Patients were divided into four groups based on the median (IQR) remnant cholesterol concentration at the time of renal biopsy. The kidney outcome was defined as ESKD, which was defined as the need for chronic kidney replacement therapy or estimated glomerular filtration rate (eGFR)\u2009&lt;\u200915\u2009mL\/min\/1.73\u2009m\n                      <jats:sup>2<\/jats:sup>\n                      . The relationship between remnant cholesterol and kidney outcome was analyzed using the Kaplan\u2012Meier method and Cox regression analysis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The mean age was 51.1 years, and 235 (70%) were men. During follow-up, a total of 121 (36.2%) patients reached ESKD. The Kaplan\u2012Meier analysis showed that patients in the highest quartile (quartile 4) group had lower cumulative renal survival (log-rank test, p\u2009=\u20090.033) and shorter median renal survival time [34.0 (26.4\u201341.6) vs. 55.0 (29.8\u201380.2) months] than patients in the lowest quartile (quartile 1) group. By univariate analysis, the high remnant cholesterol group was associated with a higher risk of progression to ESKD. Moreover, the risk of progression to ESKD in the highest quartile was still 2.857-fold (95% CI 1.305\u20136.257, p\u2009=\u20090.009) higher than that in the lowest quartile, and one-SD increase of remnant cholesterol was associated with a higher risk (HR\u2009=\u20091.424; 95% CI 1.075\u20131.886, p\u2009=\u20090.014) of progression to ESKD, after adjusted for confounding factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>High remnant cholesterol is independently associated with a higher risk of ESKD in patients with T2DM-DN, and it may be a new noninvasive marker of ESKD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical relevance<\/jats:title>\n                    <jats:p>Calculated remnant cholesterol has the advantages of being economical and clinically accessible. Moreover, to our knowledge, there are no longitudinal cohort studies for investigating the risk of progression of T2DM-DN to ESKD. In our study, higher remnant cholesterol was associated with a higher risk of ESKD in patients with T2DM-DN, and it may be a new noninvasive predictor of ESKD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12020-024-03948-4","type":"journal-article","created":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T02:02:40Z","timestamp":1723255360000},"page":"994-1002","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Remnant cholesterol and the risk of diabetic nephropathy progression to end-stage kidney disease in patients with type 2 diabetes mellitus: a longitudinal cohort study"],"prefix":"10.1007","volume":"86","author":[{"given":"Yuancheng","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutong","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yucheng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuegui","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanlin","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,12]]},"reference":[{"key":"3948_CR1","unstructured":"Magliano D.J., Boyko E.J., committee IDFDAtes. IDF Diabetes Atlas. IDF diabetes atlas. Brussels: International Diabetes Federation\u00a9 International Diabetes Federation. 2021"},{"issue":"6","key":"3948_CR2","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1001\/jama.2016.10924","volume":"316","author":"M Afkarian","year":"2016","unstructured":"M. Afkarian, L.R. Zelnick, Y.N. Hall et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988\u20132014. Jama 316(6), 602\u2013610 (2016)","journal-title":"Jama"},{"issue":"9","key":"3948_CR3","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1056\/NEJMc1602469","volume":"375","author":"L Zhang","year":"2016","unstructured":"L. Zhang, J. Long, W. Jiang et al. Trends in chronic kidney disease in China. N. Engl. J. Med. 375(9), 905\u2013906 (2016)","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"3948_CR4","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.dsx.2018.11.054","volume":"13","author":"VR A\/L B Vasanth Rao","year":"2019","unstructured":"V.R. A\/L B Vasanth Rao, S.H. Tan, M. Candasamy, S.K. Bhattamisra, Diabetic nephropathy: an update on pathogenesis and drug development. Diabetes Metab. Syndr. 13(1), 754\u2013762 (2019)","journal-title":"Diabetes Metab. Syndr."},{"issue":"9","key":"3948_CR5","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.2337\/dc11-0209","volume":"34","author":"B Eliasson","year":"2011","unstructured":"B. Eliasson, J. Cederholm, K. Eeg-Olofsson, A.M. Svensson, B. Zethelius, S. Gudbj\u00f6rnsdottir, Clinical usefulness of different lipid measures for prediction of coronary heart disease in type 2 diabetes: a report from the Swedish national diabetes register. Diabetes Care 34(9), 2095\u20132100 (2011)","journal-title":"Diabetes Care"},{"issue":"4","key":"3948_CR6","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1097\/MOL.0000000000000429","volume":"28","author":"A Varbo","year":"2017","unstructured":"A. Varbo, B.G. Nordestgaard, Remnant lipoproteins. Curr. Opin. Lipidol. 28(4), 300\u2013307 (2017)","journal-title":"Curr. Opin. Lipidol."},{"issue":"23","key":"3948_CR7","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1016\/j.jacc.2020.10.029","volume":"76","author":"JR Burnett","year":"2020","unstructured":"J.R. Burnett, A.J. Hooper, R.A. Hegele, Remnant cholesterol and atherosclerotic cardiovascular disease risk. J. Am. Coll. Cardiol. 76(23), 2736\u20132739 (2020)","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"3948_CR8","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/s12933-022-01667-6","volume":"21","author":"JH Huh","year":"2022","unstructured":"J.H. Huh, K.D. Han, Y.K. Cho et al. Remnant cholesterol and the risk of cardiovascular disease in type 2 diabetes: a nationwide longitudinal cohort study. Cardiovasc. Diabetol. 21(1), 228 (2022)","journal-title":"Cardiovasc. Diabetol."},{"issue":"24","key":"3948_CR9","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1016\/j.jacc.2022.03.384","volume":"79","author":"T Doi","year":"2022","unstructured":"T. Doi, A. Langsted, B.G. Nordestgaard, Elevated remnant cholesterol reclassifies risk of ischemic heart disease and myocardial infarction. J. Am. Coll. Cardiol. 79(24), 2383\u20132397 (2022)","journal-title":"J. Am. Coll. Cardiol."},{"issue":"12","key":"3948_CR10","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1007\/s00592-021-01765-z","volume":"58","author":"P Yan","year":"2021","unstructured":"P. Yan, Y. Xu, Y. Miao et al. Association of remnant cholesterol with chronic kidney disease in middle-aged and elderly Chinese: a population-based study. Acta Diabetol. 58(12), 1615\u20131625 (2021)","journal-title":"Acta Diabetol."},{"key":"3948_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2022.110079","volume":"191","author":"Z Wu","year":"2022","unstructured":"Z. Wu, S. Yu, Q. Zhu et al. Association of baseline and cumulative remnant cholesterol with incidence of diabetic nephropathy: a longitudinal cohort study. Diabetes Res. Clin. Pract. 191, 110079 (2022)","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"3","key":"3948_CR12","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1111\/joim.13298","volume":"290","author":"F Jansson Sigfrids","year":"2021","unstructured":"F. Jansson Sigfrids, E.H. Dahlstr\u00f6m, C. Forsblom et al. Remnant cholesterol predicts progression of diabetic nephropathy and retinopathy in type 1 diabetes. J. Intern. Med. 290(3), 632\u2013645 (2021)","journal-title":"J. Intern. Med."},{"issue":"Suppl 1","key":"3948_CR13","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.2337\/dc18-S002","volume":"41","author":"American Diabetes Association","year":"2018","unstructured":"American Diabetes Association, Classification and diagnosis of diabetes: standards of medical care in diabetes-2018. Diabetes Care 41(Suppl 1), S13\u2013s27 (2018). 2","journal-title":"Diabetes Care"},{"issue":"19 Nov","key":"3948_CR14","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","volume":"385","author":"LA Inker","year":"2021","unstructured":"L.A. Inker, N.D. Eneanya, J. Coresh et al. New creatinine- and cystatin C-based equations to estimate GFR without race. N. Engl. J. Med. 385(19 Nov), 1737\u20131749 (2021)","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"3948_CR15","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1681\/ASN.2010010010","volume":"21","author":"TW Tervaert","year":"2010","unstructured":"T.W. Tervaert, A.L. Mooyaart, K. Amann et al. Pathologic classification of diabetic nephropathy. J. Am. Soc. Nephrol. 21(4), 556\u2013563 (2010)","journal-title":"J. Am. Soc. Nephrol."},{"issue":"19 Nov","key":"3948_CR16","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1001\/jama.2013.280532","volume":"310","author":"SS Martin","year":"2013","unstructured":"S.S. Martin, M.J. Blaha, M.B. Elshazly et al. Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile. JAMA 310(19 Nov), 2061\u20132068 (2013)","journal-title":"JAMA"},{"issue":"2","key":"3948_CR17","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1681\/ASN.2017020192","volume":"29","author":"AK Mottl","year":"2018","unstructured":"A.K. Mottl, A. Gasim, F.P. Schober et al. Segmental sclerosis and extracapillary hypercellularity predict diabetic ESRD. J. Am. Soc. Nephrol. 29(2), 694\u2013703 (2018)","journal-title":"J. Am. Soc. Nephrol."},{"issue":"1","key":"3948_CR18","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12933-022-01554-0","volume":"21","author":"X Hu","year":"2022","unstructured":"X. Hu, Q. Liu, X. Guo et al. The role of remnant cholesterol beyond low-density lipoprotein cholesterol in diabetes mellitus. Cardiovasc. Diabetol. 21(1), 117 (2022)","journal-title":"Cardiovasc. Diabetol."},{"key":"3948_CR19","doi-asserted-by":"publisher","first-page":"4735","DOI":"10.2147\/DMSO.S341285","volume":"14","author":"G Xie","year":"2021","unstructured":"G. Xie, Y. Zhong, S. Yang, Y. Zou, Remnant cholesterol is an independent predictor of new-onset diabetes: a single-center cohort study. Diabetes Metab. Syndr. Obes. 14, 4735\u20134745 (2021)","journal-title":"Diabetes Metab. Syndr. Obes."},{"issue":"1","key":"3948_CR20","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12933-022-01475-y","volume":"21","author":"T Szili-Torok","year":"2022","unstructured":"T. Szili-Torok, S. Sokooti, M.C.J. Ost\u00e9 et al. Remnant lipoprotein cholesterol is associated with incident new onset diabetes after transplantation (NODAT) in renal transplant recipients: results of the TransplantLines Biobank and cohort Studies. Cardiovasc. Diabetol. 21(1), 41 (2022)","journal-title":"Cardiovasc. Diabetol."},{"issue":"1","key":"3948_CR21","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S0021-9150(02)00057-6","volume":"164","author":"H Ohnishi","year":"2002","unstructured":"H. Ohnishi, S. Saitoh, S. Takagi et al. Relationship between insulin-resistance and remnant-like particle cholesterol. Atherosclerosis 164(1), 167\u2013170 (2002)","journal-title":"Atherosclerosis"},{"issue":"1","key":"3948_CR22","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.atherosclerosis.2003.09.016","volume":"172","author":"J Funada","year":"2004","unstructured":"J. Funada, M. Sekiya, T. Otani, K. Watanabe, M. Sato, H. Akutsu, The close relationship between postprandial remnant metabolism and insulin resistance. Atherosclerosis 172(1), 151\u2013154 (2004)","journal-title":"Atherosclerosis"},{"issue":"8841","key":"3948_CR23","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/0140-6736(93)90167-F","volume":"341","author":"J Yip","year":"1993","unstructured":"J. Yip, M. Mattock, M. Sethi, A. Morocutti, G. Viberti, Insulin resistance in family members of insulin-dependent diabetic patients with microalbuminuria. Lancet 341(8841), 369\u2013370 (1993)","journal-title":"Lancet"},{"issue":"5","key":"3948_CR24","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.2337\/db05-1484","volume":"55","author":"AI Parvanova","year":"2006","unstructured":"A.I. Parvanova, R. Trevisan, I.P. Iliev et al. Insulin resistance and microalbuminuria: a cross-sectional, case-control study of 158 patients with type 2 diabetes and different degrees of urinary albumin excretion. Diabetes 55(5), 1456\u20131462 (2006)","journal-title":"Diabetes"},{"issue":"8","key":"3948_CR25","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1681\/ASN.2006121362","volume":"18","author":"L Gnudi","year":"2007","unstructured":"L. Gnudi, S.M. Thomas, G. Viberti, Mechanical forces in diabetic kidney disease: a trigger for impaired glucose metabolism. J. Am. Soc. Nephrol. 18(8), 2226\u20132232 (2007)","journal-title":"J. Am. Soc. Nephrol."},{"issue":"2","key":"3948_CR26","first-page":"206","volume":"31","author":"J Karalliedde","year":"2016","unstructured":"J. Karalliedde, L. Gnudi, Diabetes mellitus, a complex and heterogeneous disease, and the role of insulin resistance as a determinant of diabetic kidney disease. Nephrol. Dial. Transplant. 31(2), 206\u2013213 (2016)","journal-title":"Nephrol. Dial. Transplant."},{"issue":"12","key":"3948_CR27","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1161\/CIRCULATIONAHA.113.003008","volume":"128","author":"A Varbo","year":"2013","unstructured":"A. Varbo, M. Benn, A. Tybj\u00e6rg-Hansen, B.G. Nordestgaard, Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation. Circulation 128(12), 1298\u20131309 (2013)","journal-title":"Circulation"},{"issue":"12","key":"3948_CR28","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.2215\/CJN.03500412","volume":"7","author":"J Gupta","year":"2012","unstructured":"J. Gupta, N. Mitra, P.A. Kanetsky et al. Association between albuminuria, kidney function, and inflammatory biomarker profile in CKD in CRIC. Clin. J. Am. Soc. Nephrol. 7(12), 1938\u20131946 (2012)","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"22","key":"3948_CR29","doi-asserted-by":"publisher","first-page":"3635","DOI":"10.3390\/cells11223635","volume":"11","author":"A Mitrofanova","year":"2022","unstructured":"A. Mitrofanova, A.M. Fontanella, G.W. Burke, S. Merscher, A. Fornoni, Mitochondrial contribution to inflammation in diabetic kidney disease. Cells 11(22), 3635 (2022)","journal-title":"Cells"},{"issue":"42","key":"3948_CR30","doi-asserted-by":"publisher","first-page":"4324","DOI":"10.1093\/eurheartj\/ehab432","volume":"42","author":"R Quispe","year":"2021","unstructured":"R. Quispe, S.S. Martin, E.D. Michos et al. Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study. Eur. Heart J. 42(42), 4324\u20134332 (2021)","journal-title":"Eur. Heart J."},{"issue":"3","key":"3948_CR31","doi-asserted-by":"publisher","first-page":"182","DOI":"10.7326\/M13-2453","volume":"160","author":"M Tonelli","year":"2014","unstructured":"M. Tonelli, C. Wanner, Lipid management in chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2013 clinical practice guideline. Ann. Intern Med 160(3), 182 (2014)","journal-title":"Ann. Intern Med"},{"issue":"1","key":"3948_CR32","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"F. Mach, C. Baigent, A.L. Catapano et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur. Heart J. 41(1), 111\u2013188 (2020)","journal-title":"Eur. Heart J."},{"issue":"6","key":"3948_CR33","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1056\/NEJM199908053410604","volume":"341","author":"HB Rubins","year":"1999","unstructured":"H.B. Rubins, S.J. Robins, D. Collins et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans affairs high-density lipoprotein cholesterol intervention trial study group. N. Engl. J. Med 341(6), 410\u2013418 (1999)","journal-title":"N. Engl. J. Med"},{"issue":"1","key":"3948_CR34","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1161\/01.CIR.102.1.21","volume":"102","author":"Bezafibrate Infarction Prevention (BIP) study","year":"2000","unstructured":"Bezafibrate Infarction Prevention (BIP) study, Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation 102(1), 21\u201327 (2000)","journal-title":"Circulation"},{"issue":"17","key":"3948_CR35","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","volume":"362","author":"HN Ginsberg","year":"2010","unstructured":"H.N. Ginsberg, M.B. Elam, L.C. Lovato et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N. Engl. J. Med 362(17), 1563\u20131574 (2010)","journal-title":"N. Engl. J. Med"},{"issue":"4","key":"3948_CR36","doi-asserted-by":"publisher","first-page":"898","DOI":"10.2337\/dc21-1288","volume":"45","author":"HN Ginsberg","year":"2022","unstructured":"H.N. Ginsberg, N.J. Hounslow, Y. Senko et al. Efficacy and safety of K-877 (Pemafibrate), a selective PPAR\u03b1 modulator, in European patients on statin therapy. Diabetes Care 45(4), 898\u2013908 (2022)","journal-title":"Diabetes Care"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-024-03948-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-024-03948-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-024-03948-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T22:04:37Z","timestamp":1731449077000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-024-03948-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,12]]},"references-count":36,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3948"],"URL":"https:\/\/doi.org\/10.1007\/s12020-024-03948-4","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,12]]},"assertion":[{"value":"24 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol was approved by the Institutional Review Board at the West China Hospital of Sichuan University [number 2013R01].","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients provided informed consent and written informed consent was obtained from all participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}